Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Enrolling by invitation × Cyclophosphamide × Clear all

Phase

Phase 3 1 Phase 1/2 1 Phase 1 1

Status

Completed 109 Recruiting 69 Terminated 51 Active not recruiting 35 Unknown 33 Withdrawn 21 Not yet recruiting 6 Suspended 1 Enrolling by invitation 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 1

Interventions

Lenalidomide 2 irinotecan sucrosofate 1 enzalutamide 1 Ruthenium-106 1 Radiotherapy 1 Melphalan 1 Mannitol 1 Leukocyte Count 1 Irinotecan 1 Folfox protocol 1 Dexamethasone 1 Cyclophosphamide 1 Carboplatin 1 Brachytherapy 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03328026 2025-02-04

Combination Study of SV-BR-1-GM With Retifanlimab

BriaCell Therapeutics Corporation

Phase 1/2 Enrolling by invitation

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡